The Experts below are selected from a list of 54 Experts worldwide ranked by ideXlab platform
Miguel Angel Lopezruz - One of the best experts on this subject based on the ideXlab platform.
-
efficacy of pegylated interferon Plus ribavirin treatment in hiv hepatitis c virus co infected patients receiving Abacavir Plus Lamivudine or tenofovir Plus either Lamivudine or emtricitabine as nucleoside analogue backbone
Journal of Antimicrobial Chemotherapy, 2008Co-Authors: Jose A Mira, Luis F Lopezcortes, Pablo Barreiro, Cristina Tural, M Torrestortosa, Patricia Martinrico, Maria J Riosvillegas, Jose Juan Hernandezburruezo, Dolores Merino, Miguel Angel LopezruzAbstract:Objectives To compare the response to hepatitis C virus (HCV) therapy among human immunodeficiency virus (HIV)/HCV co-infected patients receiving a nucleos(t)ide reverse transcriptase inhibitor [N(t)RTI] backbone consisting of Abacavir Plus Lamivudine with that observed in subjects who receive tenofovir Plus Lamivudine or emtricitabine. Methods A total of 256 subjects, enrolled in a cohort of 948 HIV-infected patients who received pegylated interferon and ribavirin from October 2001 to January 2006, were included in this study. All patients were taking one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor and Abacavir Plus Lamivudine or tenofovir Plus Lamivudine or emtricitabine as N(t)RTI backbone during HCV therapy. Sustained virological response (SVR) rates in both backbone groups were compared. Results In an intention-to-treat analysis, 20 out of 70 (29%) individuals under Abacavir and 83 out of 186 (45%) under tenofovir showed SVR (P = 0.02). N(t)RTI backbone containing tenofovir was an independent predictor of SVR in the multivariate analysis [adjusted odds ratio (95% CI), 2.6 (1.05-6.9); P = 0.03]. The association between Abacavir use and lower SVR was chiefly seen in patients with plasma HCV-RNA load higher than 600 000 IU/mL and genotype 1 or 4. Among patients treated with ribavirin dose /=13.2 mg/kg/day. Conclusions HIV-infected patients who receive Abacavir Plus Lamivudine respond worse to pegylated interferon Plus ribavirin than those who are given tenofovir Plus Lamivudine or emtricitabine as N(t)RTI backbone, especially in those receiving lower ribavirin doses.
C Henley - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of Abacavir Plus Lamivudine versus didanosine Plus stavudine when combined with a protease inhibitor a nonnucleoside reverse transcriptase inhibitor or both in hiv 1 positive antiretroviral naive persons
Hiv Clinical Trials, 2004Co-Authors: Rodger D Macarthur, Grace Peng, Li Chen, Richard M Novak, M Van Den Bergwolf, Michael J Kozal, L Besch, Teresa Yurik, Barry Schmetter, C HenleyAbstract:Purpose: The combination of Abacavir + Lamivudine (ABC+3TC) versus didanosine + stavudine (ddI+d4T), each combined with other classes of antiretrovirals (ARVs) in ARV-naive patients, was compared for the combined endpoint of time to plasma HIV RNA >50 copies/mL (at or after the 8-month visit) or death (primary endpoint) in a nested substudy of an ongoing multicenter randomized trial. Method: The substudy enrolled 182 patients; mean HIV RNA and CD4+ cell counts at baseline were 5.1 log10 copies/mL and 212 cells/mm3, respectively. Results: After a median follow-up of 28 months, rates of primary endpoint were 57.2 and 67.8 per 100 person-years for the ABC+3TC and ddI+d4T groups (hazard ratio [HR] = 0.81, 95% confidence interval [CI] 0.58-1.14, p = .23). Conclusion: There was a trend for treatments containing ABC+3TC to be better than treatments containing ddI+d4T with respect to HIV RNA decreases, CD4+ cell count increases, and tolerability.
Jose A Mira - One of the best experts on this subject based on the ideXlab platform.
-
efficacy of pegylated interferon Plus ribavirin treatment in hiv hepatitis c virus co infected patients receiving Abacavir Plus Lamivudine or tenofovir Plus either Lamivudine or emtricitabine as nucleoside analogue backbone
Journal of Antimicrobial Chemotherapy, 2008Co-Authors: Jose A Mira, Luis F Lopezcortes, Pablo Barreiro, Cristina Tural, M Torrestortosa, Patricia Martinrico, Maria J Riosvillegas, Jose Juan Hernandezburruezo, Dolores Merino, Miguel Angel LopezruzAbstract:Objectives To compare the response to hepatitis C virus (HCV) therapy among human immunodeficiency virus (HIV)/HCV co-infected patients receiving a nucleos(t)ide reverse transcriptase inhibitor [N(t)RTI] backbone consisting of Abacavir Plus Lamivudine with that observed in subjects who receive tenofovir Plus Lamivudine or emtricitabine. Methods A total of 256 subjects, enrolled in a cohort of 948 HIV-infected patients who received pegylated interferon and ribavirin from October 2001 to January 2006, were included in this study. All patients were taking one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor and Abacavir Plus Lamivudine or tenofovir Plus Lamivudine or emtricitabine as N(t)RTI backbone during HCV therapy. Sustained virological response (SVR) rates in both backbone groups were compared. Results In an intention-to-treat analysis, 20 out of 70 (29%) individuals under Abacavir and 83 out of 186 (45%) under tenofovir showed SVR (P = 0.02). N(t)RTI backbone containing tenofovir was an independent predictor of SVR in the multivariate analysis [adjusted odds ratio (95% CI), 2.6 (1.05-6.9); P = 0.03]. The association between Abacavir use and lower SVR was chiefly seen in patients with plasma HCV-RNA load higher than 600 000 IU/mL and genotype 1 or 4. Among patients treated with ribavirin dose /=13.2 mg/kg/day. Conclusions HIV-infected patients who receive Abacavir Plus Lamivudine respond worse to pegylated interferon Plus ribavirin than those who are given tenofovir Plus Lamivudine or emtricitabine as N(t)RTI backbone, especially in those receiving lower ribavirin doses.
-
Efficacy of pegylated interferon Plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving Abacavir Plus Lamivudine or tenofovir Plus either Lamivudine or emtricitabine as nucleoside analogue backbone
Journal of Antimicrobial Chemotherapy, 2008Co-Authors: Jose A Mira, Pablo Barreiro, Cristina Tural, Luis F. López-cortés, M. Torres-tortosa, Patricia Martín-rico, María J. Ríos-villegas, José Juan Hernández-burruezo, Dolores MerinoAbstract:Objectives To compare the response to hepatitis C virus (HCV) therapy among human immunodeficiency virus (HIV)/HCV co-infected patients receiving a nucleos(t)ide reverse transcriptase inhibitor [N(t)RTI] backbone consisting of Abacavir Plus Lamivudine with that observed in subjects who receive tenofovir Plus Lamivudine or emtricitabine. Methods A total of 256 subjects, enrolled in a cohort of 948 HIV-infected patients who received pegylated interferon and ribavirin from October 2001 to January 2006, were included in this study. All patients were taking one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor and Abacavir Plus Lamivudine or tenofovir Plus Lamivudine or emtricitabine as N(t)RTI backbone during HCV therapy. Sustained virological response (SVR) rates in both backbone groups were compared. Results In an intention-to-treat analysis, 20 out of 70 (29%) individuals under Abacavir and 83 out of 186 (45%) under tenofovir showed SVR (P = 0.02). N(t)RTI backbone containing tenofovir was an independent predictor of SVR in the multivariate analysis [adjusted odds ratio (95% CI), 2.6 (1.05-6.9); P = 0.03]. The association between Abacavir use and lower SVR was chiefly seen in patients with plasma HCV-RNA load higher than 600 000 IU/mL and genotype 1 or 4. Among patients treated with ribavirin dose /=13.2 mg/kg/day. Conclusions HIV-infected patients who receive Abacavir Plus Lamivudine respond worse to pegylated interferon Plus ribavirin than those who are given tenofovir Plus Lamivudine or emtricitabine as N(t)RTI backbone, especially in those receiving lower ribavirin doses.
Lesley J. Scott - One of the best experts on this subject based on the ideXlab platform.
-
Abacavir Plus Lamivudine
Drugs, 2005Co-Authors: Toni M. Dando, Lesley J. ScottAbstract:Abacavir and Lamivudine (two nucleoside analogue reverse transcriptase inhibitors [NRTIs]), as separate formulations in combination with other antiretroviral agents, are effective in the reduction of HIV RNA levels in antiretroviral-naive patients with HIV infection, and are generally well tolerated. A fixed-dose combination tablet of Abacavir/Lamivudine (Epzicom™, Kivexa™) has been developed for once-daily use and preliminary efficacy data are promising. Although further experience with this formulation is needed to fully determine its position in the management of HIV infection, a single, once-daily tablet that may be taken irrespective of food intake should aid adherence to treatment, a key factor in determining the success of an antiretroviral regimen. Thus, Abacavir and Lamivudine are two established components of first-line antiretroviral regimens for the management of HIV infection and the fixed-dose Abacavir/Lamivudine tablet has the potential to be an effective, easily adhered to and generally well tolerated component of first-line therapy. Pharmacological Properties The active metabolites of Abacavir and Lamivudine inhibit the HIV reverse transcriptase enzyme. The two drugs show additive or synergistic in vitro activity against HIV isolates. HIV variants with reduced susceptibility to Abacavir or Lamivudine have been selected for in vitro and have also been isolated from patients receiving Abacavir and/or Lamivudine. Both drugs select for a methionine to valine substitution at position 184 (M184V) of the HIV reverse transcriptase enzyme. Other substitutions associated with Abacavir monotherapy are leucine to valine at position 74 (L74V), lysine to arginine at position 65 (K65R) and tyrosine to phenylalanine at position 115 (Y115F). A single dose of fixed-dose Abacavir/Lamivudine 600mg/300mg was bioequivalent to single doses of Abacavir 600mg Plus Lamivudine 300mg, based on the values for systemic absorption and peak plasma concentration in healthy volunteers. Systemic exposure to the drugs following administration of the fixed-dose tablet is not altered by food. Abacavir and Lamivudine are both rapidly absorbed after oral administration. Both drugs are eliminated predominantly in the urine: Abacavir primarily as metabolites and Lamivudine mainly unchanged. The pharmacokinetic properties of Abacavir and Lamivudine, including the intracellular pharmacokinetics of their active metabolites, support their use as once-daily therapy. Therapeutic Efficacy Abacavir Plus Lamivudine (administered as separate formulations) have shown efficacy as the backbone of triple or quadruple antiretroviral therapy for antiretroviral-naive adult patients with HIV infection. When concomitant Abacavir and Lamivudine were used in combination with another NRTI, a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor for 48 weeks, up to 76.3% of recipients achieved plasma HIV RNA levels of
-
Abacavir Plus Lamivudine a review of their combined use in the management of hiv infection
Drugs, 2005Co-Authors: Toni M. Dando, Lesley J. ScottAbstract:Abstract Abacavir and Lamivudine (two nucleoside analogue reverse transcriptase inhibitors [NRTIs]), as separate formulations in combination with other antiretroviral agents, are effective in the reduction of HIV RNA levels in antiretroviral-naive patients with HIV infection, and are generally well tolerated. A fixed-dose combination tablet of Abacavir/Lamivudine (Epzicom™, Kivexa™) has been developed for once-daily use and preliminary efficacy data are promising. Although further experience with this formulation is needed to fully determine its position in the management of HIV infection, a single, once-daily tablet that may be taken irrespective of food intake should aid adherence to treatment, a key factor in determining the success of an antiretroviral regimen. Thus, Abacavir and Lamivudine are two established components of first-line antiretroviral regimens for the management of HIV infection and the fixed-dose Abacavir/Lamivudine tablet has the potential to be an effective, easily adhered to and generally well tolerated component of first-line therapy.
Dolores Merino - One of the best experts on this subject based on the ideXlab platform.
-
efficacy of pegylated interferon Plus ribavirin treatment in hiv hepatitis c virus co infected patients receiving Abacavir Plus Lamivudine or tenofovir Plus either Lamivudine or emtricitabine as nucleoside analogue backbone
Journal of Antimicrobial Chemotherapy, 2008Co-Authors: Jose A Mira, Luis F Lopezcortes, Pablo Barreiro, Cristina Tural, M Torrestortosa, Patricia Martinrico, Maria J Riosvillegas, Jose Juan Hernandezburruezo, Dolores Merino, Miguel Angel LopezruzAbstract:Objectives To compare the response to hepatitis C virus (HCV) therapy among human immunodeficiency virus (HIV)/HCV co-infected patients receiving a nucleos(t)ide reverse transcriptase inhibitor [N(t)RTI] backbone consisting of Abacavir Plus Lamivudine with that observed in subjects who receive tenofovir Plus Lamivudine or emtricitabine. Methods A total of 256 subjects, enrolled in a cohort of 948 HIV-infected patients who received pegylated interferon and ribavirin from October 2001 to January 2006, were included in this study. All patients were taking one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor and Abacavir Plus Lamivudine or tenofovir Plus Lamivudine or emtricitabine as N(t)RTI backbone during HCV therapy. Sustained virological response (SVR) rates in both backbone groups were compared. Results In an intention-to-treat analysis, 20 out of 70 (29%) individuals under Abacavir and 83 out of 186 (45%) under tenofovir showed SVR (P = 0.02). N(t)RTI backbone containing tenofovir was an independent predictor of SVR in the multivariate analysis [adjusted odds ratio (95% CI), 2.6 (1.05-6.9); P = 0.03]. The association between Abacavir use and lower SVR was chiefly seen in patients with plasma HCV-RNA load higher than 600 000 IU/mL and genotype 1 or 4. Among patients treated with ribavirin dose /=13.2 mg/kg/day. Conclusions HIV-infected patients who receive Abacavir Plus Lamivudine respond worse to pegylated interferon Plus ribavirin than those who are given tenofovir Plus Lamivudine or emtricitabine as N(t)RTI backbone, especially in those receiving lower ribavirin doses.
-
Efficacy of pegylated interferon Plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving Abacavir Plus Lamivudine or tenofovir Plus either Lamivudine or emtricitabine as nucleoside analogue backbone
Journal of Antimicrobial Chemotherapy, 2008Co-Authors: Jose A Mira, Pablo Barreiro, Cristina Tural, Luis F. López-cortés, M. Torres-tortosa, Patricia Martín-rico, María J. Ríos-villegas, José Juan Hernández-burruezo, Dolores MerinoAbstract:Objectives To compare the response to hepatitis C virus (HCV) therapy among human immunodeficiency virus (HIV)/HCV co-infected patients receiving a nucleos(t)ide reverse transcriptase inhibitor [N(t)RTI] backbone consisting of Abacavir Plus Lamivudine with that observed in subjects who receive tenofovir Plus Lamivudine or emtricitabine. Methods A total of 256 subjects, enrolled in a cohort of 948 HIV-infected patients who received pegylated interferon and ribavirin from October 2001 to January 2006, were included in this study. All patients were taking one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor and Abacavir Plus Lamivudine or tenofovir Plus Lamivudine or emtricitabine as N(t)RTI backbone during HCV therapy. Sustained virological response (SVR) rates in both backbone groups were compared. Results In an intention-to-treat analysis, 20 out of 70 (29%) individuals under Abacavir and 83 out of 186 (45%) under tenofovir showed SVR (P = 0.02). N(t)RTI backbone containing tenofovir was an independent predictor of SVR in the multivariate analysis [adjusted odds ratio (95% CI), 2.6 (1.05-6.9); P = 0.03]. The association between Abacavir use and lower SVR was chiefly seen in patients with plasma HCV-RNA load higher than 600 000 IU/mL and genotype 1 or 4. Among patients treated with ribavirin dose /=13.2 mg/kg/day. Conclusions HIV-infected patients who receive Abacavir Plus Lamivudine respond worse to pegylated interferon Plus ribavirin than those who are given tenofovir Plus Lamivudine or emtricitabine as N(t)RTI backbone, especially in those receiving lower ribavirin doses.
